314 related articles for article (PubMed ID: 38539569)
1. Cross-Talks between Raf Kinase Inhibitor Protein and Programmed Cell Death Ligand 1 Expressions in Cancer: Role in Immune Evasion and Therapeutic Implications.
Ho M; Bonavida B
Cells; 2024 May; 13(10):. PubMed ID: 38786085
[TBL] [Abstract][Full Text] [Related]
2. Reprogramming exosomes for immunity-remodeled photodynamic therapy against non-small cell lung cancer.
Guo J; Zhao W; Xiao X; Liu S; Liu L; Zhang L; Li L; Li Z; Li Z; Xu M; Peng Q; Wang J; Wei Y; Jiang N
Bioact Mater; 2024 Sep; 39():206-223. PubMed ID: 38827172
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Immunosuppressive Tumors by Polymer-Assisted Inductions of Immunogenic Cell Death and Multivalent PD-L1 Crosslinking.
Li L; Li Y; Yang CH; Radford DC; Wang J; Janát-Amsbury M; Kopeček J; Yang J
Adv Funct Mater; 2020 Mar; 30(12):. PubMed ID: 33071706
[TBL] [Abstract][Full Text] [Related]
4. An updated review of immunotherapy in esophageal cancer: PD-L1 footprint.
Yao J; Tan X; Sha Y; Chen Y; Chen R; Shi D
Cent Eur J Immunol; 2024; 49(1):77-90. PubMed ID: 38812606
[TBL] [Abstract][Full Text] [Related]
5. A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells.
David JM; Dominguez C; McCampbell KK; Gulley JL; Schlom J; Palena C
Oncoimmunology; 2017; 6(10):e1349589. PubMed ID: 29123964
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint Inhibitors and Their Application in Breast Cancer.
Bedognetti D; Maccalli C; Bader SB; Marincola FM; Seliger B
Breast Care (Basel); 2016 Apr; 11(2):108-15. PubMed ID: 27239172
[TBL] [Abstract][Full Text] [Related]
7. Relationship of Metabolic Alterations and PD-L1 Expression in Cisplatin Resistant Lung Cancer.
Wangpaichitr M; Kandemir H; Li YY; Wu C; Nguyen D; Feun LG; Kuo MT; Savaraj N
Cell Dev Biol; 2017 Jun; 6(2):. PubMed ID: 28819582
[TBL] [Abstract][Full Text] [Related]
8. LRP1 induces anti-PD-1 resistance by modulating the DLL4-NOTCH2-CCL2 axis and redirecting M2-like macrophage polarisation in bladder cancer.
Lin H; Fu L; Zhou X; Yu A; Chen Y; Liao W; Shu G; Zhang L; Tan L; Liang H; Wang Z; Deng Q; Wang J; Jin M; Chen Z; Wei J; Cao J; Chen W; Li X; Li P; Lu J; Luo J
Cancer Lett; 2024 Jul; 593():216807. PubMed ID: 38462037
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 at the crossroad between RNA metabolism and immunosuppression.
Arthur A; Nejmi S; Franchini DM; Espinos E; Millevoi S
Trends Mol Med; 2024 May; ():. PubMed ID: 38824002
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, and Biological Evaluation of Chroman Derivatives as PD-1/PD-L1 Antagonists.
Wang L; Hou J; Cao P; Yao Z; Wang S; Zhang Y; Wang S; Yuan H; Liu L
J Chem Inf Model; 2024 Jun; ():. PubMed ID: 38856697
[TBL] [Abstract][Full Text] [Related]
11. Posttranslational regulatory mechanism of PD-L1 in cancers and associated opportunities for novel small-molecule therapeutics.
Cai M; Xu M; Yu D; Wang Q; Liu S
Acta Biochim Biophys Sin (Shanghai); 2024 Jun; ():. PubMed ID: 38826132
[TBL] [Abstract][Full Text] [Related]
12. Virtual clinical trials via a QSP immuno-oncology model to simulate the response to a conditionally activated PD-L1 targeting antibody in NSCLC.
Ippolito A; Wang H; Zhang Y; Vakil V; Popel AS
J Pharmacokinet Pharmacodyn; 2024 Jun; ():. PubMed ID: 38858306
[TBL] [Abstract][Full Text] [Related]
13. YY1 regulates cancer cell immune resistance by modulating PD-L1 expression.
Hays E; Bonavida B
Drug Resist Updat; 2019 Mar; 43():10-28. PubMed ID: 31005030
[TBL] [Abstract][Full Text] [Related]
14. Nitric Oxide-Mediated Enhancement and Reversal of Resistance of Anticancer Therapies.
Hays E; Bonavida B
Antioxidants (Basel); 2019 Sep; 8(9):. PubMed ID: 31533363
[TBL] [Abstract][Full Text] [Related]
15. Isorhamnetin and anti-PD-L1 antibody dual-functional mesoporous silica nanoparticles improve tumor immune microenvironment and inhibit YY1-mediated tumor progression.
Liu H; Han J; Lv Y; Zhao Z; Zheng S; Sun Y; Sun T
J Nanobiotechnology; 2023 Jul; 21(1):208. PubMed ID: 37408047
[TBL] [Abstract][Full Text] [Related]
16. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
17. Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy
Zhou X; Zou L; Liao H; Luo J; Yang T; Wu J; Chen W; Wu K; Cen S; Lv D; Shu F; Yang Y; Li C; Li B; Mao X
Acta Pharm Sin B; 2022 Feb; 12(2):692-707. PubMed ID: 35256940
[TBL] [Abstract][Full Text] [Related]
18. Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1.
Dillen A; Bui I; Jung M; Agioti S; Zaravinos A; Bonavida B
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539569
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
